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Abstract
Cardiopulmonary bypass (CPB) is often necessary for congenital cardiac surgery, 
but CPB can alter drug pharmacokinetic parameters resulting in underdosing. 
Inadequate plasma levels of antibiotics could lead to postoperative infections with 
increased morbidity. The influence of pediatric CPB systems on cefazolin and clin-
damycin plasma levels is not known. We have measured plasma levels of cefazolin 
and clindamycin in in vitro pediatric CPB systems. We have tested three types of 
CPB systems. All systems were primed and spiked with clindamycin and cefazolin. 
Samples were taken at different time points to measure the recovery of cefazolin and 
clindamycin. Linear mixed model analyses were performed to assess if drug recovery 
was different between the type of CPB system and sampling time point. The experi-
ments were conducted at a tertiary university hospital. 81 samples were analyzed. 
There was a significant difference in the recovery over time between CPB systems 
for cefazolin and clindamycin (P < .001). Cefazolin recovery after 180 minutes was 
106% (95% CI: 91-123) for neonatal, 99% (95% CI: 85-115) for infant, and 77% (95% 
CI: 67-89) for pediatric systems. Clindamycin recovery after 180 minutes was 143% 
(95% CI: 116-177) for neonatal, 111% (95% CI: 89-137) for infant, and 120% (95% 
CI: 97-149) for pediatric systems. Clindamycin recovery after 180 minutes compared 
to the theoretical concentration was 0.4% for neonatal, 1.2% for infants, and 0.6% 
for pediatric systems. The recovery of cefazolin was high in the neonatal and infant 
CPB systems and moderate in the pediatric system. We found a large discrepancy 
between the theoretical and measured concentrations of clindamycin in all tested 
CPB systems.
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1  |  INTRODUCTION
During pediatric cardiac surgery, the use of the cardiopul-
monary bypass (CPB) is often necessary. However, CPB has 
several effects that can alter drug pharmacokinetic parame-
ters leading to potentially increased or decreased plasma drug 
concentration in the patient. This may be a problem when 
dosing antibiotics to prevent surgical site infections (SSI), 
since inadequate antibiotic plasma concentration may lead to 
an increased risk to develop SSI and subsequent morbidity 
and mortality.1
The most profound changes CPB systems induce on drug 
concentrations are due to hemodilution, causing changes in 
drug distribution and clearance, changed hemodynamic sta-
tus and protein binding, hypothermia and occasionally hemo-
filtration. The influence of these changes on plasma drug 
concentration is known for some routinely used drugs, such 
as midazolam and propofol.2
The CPB system itself has an effect on drugs adminis-
tered during surgery. Mainly lipophilic drugs are known to 
sequester in the CPB system.3,4 Factors that can contribute 
are type and coating of tubing,5,6 and the type of priming 
fluid.2 Studies on the effects of CPB on plasma levels of 
drugs have not been performed recently and may no longer 
be comparable to current practice, since CPB systems and 
perioperative management may have changed. Data on pedi-
atric CPB systems are lacking, since the literature published 
on in vitro assessment of the CPB systems investigates only 
adult CPB systems. The size of the system, added volume, 
and composition of priming fluid are different in adult CPB 
systems compared to pediatric CPB systems and data from 
adult CPB systems cannot simply be extrapolated to pediatric 
systems.
We have designed the CPB-PHARM study to investigate 
the influence of CPB on routinely used drugs during and after 
pediatric cardiac surgery (MEC2011-400). We have added an 
in vitro substudy to investigate the effects of the CPB with-
out the influence of surgery or patients. This in vitro study 
describes the influence of different pediatric CPB systems 
on plasma levels of cefazolin and clindamycin, our first and 
second choice antibiotic prophylaxis.
2 |  MATERIALS AND METHODS
We have investigated three types of pediatric CPB systems 
used at the Department of Cardio-Thoracic Surgery of the 
Erasmus MC, Rotterdam, The Netherlands. Since all experi-
ments were in vitro and no patients were involved, there is 
no issue of informed consent in accordance with Dutch law. 
Circuits that would soon expire were made available free 
of charge by Terumo Europe NV, Leuven, Belgium and 
Sorin Group, Mirandola, Italy. Terumo Europe NV and 
Sorin Group had no influence on study design and protocol, 
data collection and analyses, or publication.
2.1 | CPB systems
We have tested three CPB systems used for congenital cardiac 
surgery in our institution. The neonatal, infant, and pediatric 
CPB systems are used for patients with bodyweights of under 
10, 10-20, and 20-40 kg, respectively. An overview of the com-
ponents of these CPB systems is given in Table 1. In summary, 
all systems consist of a hollow-fiber oxygenator and an open 
hard-shell reservoir. The oxygenator of the neonatal and pedi-
atric systems is coated with X-coating (poly(2-methoxyethyl 
acrylate) (PMEA)), a nonheparin biocompatible polymer with 
hydrophilic and hydrophobic properties. The neonatal and 
pediatric systems have an integrated arterial filter, whereas 
the infant system has a stand-alone arterial filter. The arterial 
filter is a polyester screen-type filter in the neonatal and pedi-
atric systems and a phosporylcholine screen-type filter in the 
infant system, with varying surface areas. The venous reser-
voirs are made of polycarbonate with capacities of 1000, 1500, 
and 3000-4000 mL, respectively, for the neonatal, infant, and 
pediatric CPB systems. A roller pump is used in the neonatal 
and infant systems. In the pediatric system, a centrifugal pump 
is used, with a pump casing of polycarbonate. A combination 
of silicone and polyvinylchloride (PVC) tubing is used in the 
neonatal and infant systems. In the pediatric system, only PVC 
tubing is used. The tubing in all systems is coated with Phisio 
coating: a nonheparin, biomimetic layer consisting of a phos-
phorylcholine polymer.
Three systems were assembled for each category and 
placed on a mast-mounted, remote pump head console 
(Stöcker S5 Perfusion System, Sorin Group, Mirandola, 
Italy), with a pediatric configuration. A ¼-¼ or a ¼-⅜ con-
nection piece was used to make the continuous CPB systems.
All systems were primed according to hospital protocol 
(Table 2). Priming fluid in all systems consists of fresh frozen 
plasma (FFP), Gelofusine (B. Braun, Melsungen, Germany), red 
blood cells (RBCs), human albumin (Sanquin Plasma Products 
BV, Amsterdam, The Netherlands), and sodium bicarbonate 
8.4% (Fresenius Kabi Nederland BV, Zeist, NL). Heparin was 
added to avoid the clotting of blood in the system. Hematocrit 
was aimed to be 28% during CPB. FFP’s and RBC’s those were 
just expired were obtained from the local blood bank.
CPB systems were kept running at a temperature of 36°C 
for 6 hours, since this is the maximum runtime for which the 
quality is guaranteed by the manufacturers. Before the start 
of the experiments the pCO2, pO2, and pH were measured 
with iStat (Abbot BV, Hoofddorp, The Netherlands). These 
parameters were kept within physiologic ranges during the 
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experiments using sweep gas flow, gas composition and if 
needed, additional of sodium bicarbonate 8.4%.
Flow rates were kept at 0.5, 1.5, and 3  L/min for the 
neonatal, infant, and pediatric CPB systems. Using the ve-
nous clamp, postmembrane pressures were kept constant at 
100 mm Hg.
2.2 | Drug administration
Drug doses were standardized based on the average weight for 
a patient for the neonatal, infant, and pediatric CPB system. 
Drugs for the neonatal system were based on a 5 kg patient, 
for the infant system on a 15 kg patient, and for the pediat-
ric system a 30 kg patient. Drugs were dosed according to our 
institutional guidelines for the induction for general anesthe-
sia, that is, cefazolin at 30 mg/kg and clindamycin at 12 mg/kg 
for neonates and 6.7 mg/kg for children with a body weight of 
above 10 kg (see Table 3).
Drugs were injected into the CPB systems at the venous 
side of the system via a manifold sample port. After each 
drug, 2 mL of physiological saline solution (0.9%) flush was 
injected to prevent pooling or crystallization of drugs in the 
sample port. Drugs were administered in the same order for 
all systems and all experiments.
2.3 | Samples
From each CPB system, 4 mL of blood samples was taken 
at different time points. The first samples were immediately 
after injection of the drugs (T1), thereafter samples were 
taken at 2, 5, 7, 10, 30, 60, 180, and 300 minutes. Samples 
were taken from the arterial (postoxygenator) side of the CPB 
system via a manifold sample port. Polypropylene EDTA 
tubes were used (7.2  mg EDTA, BD Vacutainer, BD Life 
Sciences, Plymouth, UK).
Samples were stored at 4°C until centrifugation (10 min-
utes at 3600 rpm). The supernatant serum was transferred to 
polypropylene cryogenic vials with polypropylene screw caps 
(Sarstedt Aktiengesellschaft & Co, Nümbrecht, Germany) and 
stored at −80°C until further analysis.
2.4 | Assay methods
Liquid chromatography-mass spectrometry (LC-MS/MS) 
was used to measure the total plasma drug concentrations of 
cefazolin and clindamycin.
Drug concentrations for clindamycin were measured using 
LC-MS/MS in a Thermo TSQ Quantiva triple-stage quadru-
pole mass spectrometer (Thermo Fisher Scientific, Waltham, 
MA, USA) at the pharmacy laboratory of the University 
Medical Center Groningen, The Netherlands.
Drug concentrations for cefazolin were measured using 
LC-MS/MS in an AB SCIEX QTRAP 5500 triple quadrupole 
mass spectrometer (AB SCIEX, Concord, Ontario, Canada) 
and Analyst software version 1.6.2 (AB SCIEX, Concord, 
Ontario, Canada) at the IBMP Institute for Biomedical 
and Pharmaceutical Research in Nürnberg-Heroldsberg, 
Germany.
Limits of quantification are specified in Table 4. A certi-
fied research technician from the ISO-certified laboratories 
performed the FDA validated drug analyses. In all analyses, 
quality control samples are included, as is obliged in FDA 
analyses and ISO and GCP certified laboratory.
2.5 | Statistical analysis
We performed linear mixed model analyses with drug con-
centration as the dependent variable and type of CPB system 
and sample time point as independent variables. We used 
mixed models analysis because a correlation can be expected 
between multiple measurements of the same variable (drug 
concentration) in the same subject (CPB systems). Given the 
nonnormal distribution of the drug concentrations, the depend-
ent variable in the linear mixed model was defined as the log-
transformed concentration of cefazolin and clindamycin. The 
independent variables were treated as categorical variables 
and an interaction effect between the independent variables 
was included in the model. We used a random intercept and 
assumed a first-order autoregressive error covariance matrix 
to correct for within-system correlations between time points. 
This model specification was chosen by comparing the values 
of the Akaike information criterion between different struc-
tures for the random effects and the error covariance matrix.
The predicted values for the log-transformed concen-
tration for each CPB system and at each time point were 
provided by the linear mixed models. We calculated the 
T A B L E  2  Prime fluid
  Neonatal Infant Pediatric
Priming volume (mL) 263.4 430 683
RBC (mL) 135 235 365
FFP (mL) 30 40 50
Gelofusine (mL) 30 40 50
Albumin 20 % (mL) 40 50 100
Mannitol 15 % (mL 20 50 100
NaHCO3 8.4 % (mL) 3 15 18
Heparin (mL) 0.4 0.5 1
Flow (L/min) 0.5 1.5 3
Temperature (°C) 36 36 36
Line pressure (mm Hg) 100 100 100
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differences between the predicted values for each time point 
and each CPB system and T1, including the 95% Confidence 
Interval (95% CI) of this difference. We exponentiated this 
difference and the 95% CI to obtain drug recovery (percent-
age of drugs still present in the system) for T2 to T300. We 
calculated the maximum expected concentration (MEC) of 
the drug in the CPB systems by dividing the amount of drug 
added to the CPB systems by the total priming volume in the 
systems. We used the MEC since it was unclear whether the 
drug was mixed completely with the prime fluid at T1.
Statistical analyses were performed using IBM SPSS 
Statistics 24 and all statistical tests used a two-sided signifi-
cance level of 0.05.
3 |  RESULTS
A total of 81 samples, 27 for each CPB system category, was 
analyzed. We encountered no technical problems during the 
execution of the experiments.
Figure 1 shows predicted drug recovery (based on the es-
timated marginal means of the linear mixed models) versus 
time for cefazolin and clindamycin, for each CPB-system cat-
egory. Based on the interaction effects in the mixed models, 
there was a significant difference in the pattern of recovery 
over time between systems for both cefazolin and clindamy-
cin (P < .001). For cefazolin, the lowest drug recovery was in 
the pediatric systems, while the highest drug recovery was in 
the neonatal systems. In the pediatric system, cefazolin con-
centration seems to show an initial decline, but then increased 
again to the starting drug concentration. This maximum in 
recovered concentration was found after two hours of CPB 
runtime. After these first two hours cefazolin concentration 
decreased to approximately 50% recovery at the end of the 
experiment.
For clindamycin, the highest recovery was observed in 
the neonatal systems, while the lowest recovery was in the 
infant systems. The clindamycin concentration was relatively 
stable during the experiment, with a mild increase in drug 
recovery in all systems starting at 60 minutes to the end of 
the experiment.
Mean recovery for cefazolin after 60 and 180  minutes, 
compared to T1, was 94% (95% CI: 81-109) and 106% (95% 
CI: 91-123) for the neonatal systems, 96% (95% CI: 83-112) 
and 99% (95% CI: 85-115) for the infant systems, and 124% 
(95% CI: 107-144) and 77% (95% CI: 67-89) for the pediatric 
systems.
Mean recovery for clindamycin after 60 and 180 minutes, 
compared to T1, was 110% (95% CI: 89-136) and 143% (95% 
CI: 116-177) for the neonatal CPB systems, 99% (95% CI: 
80-123) and 111% (95% CI: 89-137) for the infant systems, 
and 107% (95% CI: 86-132) and 120% (95% CI: 97-149) for 
the pediatric systems.
For cefazolin the MEC was in the range of the measure-
ments of T1 and T2, indicating complete mixing of cefazolin 
after injection in the CB system. For clindamycin MEC was 
much higher than all measurements, indicating a steep de-
cline after injection. Mean clindamycin recovery after 60 and 
180 minutes compared to the MEC was 0.3% and 0.4% for 
neonatal systems, 1.1% and 1.2% for infants’ systems, and 
0.5% and 0.6% for pediatric systems.
4 |  DISCUSSION
The influence of pediatric CPB systems on plasma drug con-
centration is largely unknown. However, the use of CPB is 
inevitable in most congenital cardiac surgery procedures. For 
adult patients, in vivo and in vitro studies have been pub-
lished.4,7‒9 We have investigated cefazolin and clindamycin 
plasma concentrations in three pediatric CPB systems that 
are used in our institution.
For cefazolin, there are no previous in vitro publications 
for adult or pediatric CPB systems. However, cefazolin was 
investigated in vitro in pediatric extracorporeal membrane 
oxygenation systems (ECMO).10 In these experiments, the 
recovery of cefazolin was high for both neonatal and pe-
diatric ECMO systems, with an average cefazolin recov-
ery at 2 minutes of 87%, and recovery at 180 minutes of 
84.3%, with almost no difference between systems. After 
approximately 10 minutes plasma cefazolin concentration 
reached a steady state. These results are much in line with 
our findings. Our findings indicate that cefazolin mixes 
within minutes in the CPB systems and concentration 
T A B L E  3  Drug concentration administered to the CPB systems
  Neonate (mg) Infant (mg) Pediatric (mg)
Cefazolin (Kefzol, Eurocept BV, Ankeveen, The Netherlands, 100 mg/mL) 250 750 1500
Clindamycin (Dalacin, Pfizer BV, Capelle aan den IJssel, The Netherlands) 60 100 200
T A B L E  4  Limits of quantification
Drug
Lower limit of quanti-
fication (mg/L)
Upper limit of quan-
tification (mg/L)
Cefazolin 209.3 2009.23
Clindamycin 0.6 57.00
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moderately decreases throughout the experiments. Only 
in our pediatric systems the cefazolin concentration de-
creased by 50% by the end of the experiment. We cannot 
fully explain this decrease in only the pediatric systems. 
The components of the neonatal and pediatric CPB systems 
are similar and cefazolin plasma concentration is stable in 
the neonatal systems. The type and length of tubing could 
make a difference, with a larger contact surface area in the 
pediatric CPB systems. Absorption of drugs to PVC tub-
ing with various coatings has been shown for fentanyl and 
morphine. This may also affect the cefazolin plasma con-
centration and account for the more profound decrease in 
the larger CPB system. Recently, De Cock et al published 
in vivo data on cefazolin plasma concentration during and 
after pediatric cardiac surgery.11 The authors collected 
blood samples from children undergoing cardiac surgery 
and concentration-time profiles were analyzed using popu-
lation pharmacokinetic modeling.12 The authors estimated 
that the volume of distribution of the CPB compartment in 
the pharmacokinetic model was equal to the priming vol-
ume of the CPB system. This means there should be no 
sequestration of cefazolin in the CPB system. However, the 
duration of surgical procedure and subsequent CPB use was 
the primary factor for not achieving the optimal cefazolin 
plasma levels. Considering the apparent lack of sequestra-
tion in the CPB systems, other factors may be responsible 
for the moderate decrease in cefazolin plasma levels that 
are not yet understood.
For clindamycin, the measured plasma concentrations re-
mained stable over time, but the difference between the MEC 
and measured plasma concentration was large. These results 
were comparable for all tested CPB systems.
There are no previous studies published on the clinda-
mycin use during cardiac surgery in adults or children. Our 
results, therefore, are the first to present these plasma concen-
trations. Measured clindamycin concentration remains stable 
during the CPB run, with an increase in the concentration to-
ward the end of the experiment. This mild increase may be 
due to the recirculation of clindamycin from tubing or other 
CPB components. The most striking result is the large differ-
ence between the MEC and the first measured plasma concen-
tration. This large difference may have several reasons. The 
first reason may be incomplete mixing of clindamycin with 
the prime fluid after injection in the CPB systems. This may 
lead to a preferential flow in the reservoir causing clindamycin 
to precipitate without circulating in the entire CPB system. 
An open hard-shell reservoir is used in all CPB systems and 
this may be the compartment to cause clindamycin precipita-
tion. However, we cannot explain the cause of precipitation 
other than incomplete mixing. Another potential cause for 
the discrepancy between MEC and measured concentration 
is sequestration of clindamycin to the plastic components or 
the defoaming area in the CPB system. Hydrophilic drugs 
such as clindamycin are not known to sequester in CPB sys-
tems. Sequestration in these systems is expected for lipophilic 
drugs, such as sufentanil or midazolam.13 As shown by Shekar 
et al14 in ECMO circuits, drugs with a LogP greater than 2.3 
have a significantly higher decrease in the concentration com-
pared to less lipophilic or hydrophilic drugs. As both cefazolin 
and clindamycin have a lower LogP they are not expected to 
sequester in the CPB systems (see Table 5).
Highly protein-bound drugs (>80% protein bound) also 
sequester significantly more in ECMO systems and this could 
be a possible cause for the sequestration of clindamycin, 
F I G U R E  1  Predicted recovery of cefazolin and clindamycin (in % of theoretical concentration) versus time [Color figure can be viewed at 
wileyonlinelibrary.com]
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since clindamycin is strongly protein bound. The Vd of clin-
damycin is mainly influenced by albumin and alpha-1 acid 
glycoprotein.15 Albumin, but not alpha-1 acid glycoprotein 
was added to the prime fluid and may have caused a shift in 
clindamycin protein binding resulting in a higher unbound 
fraction. However, we have measured the total serum con-
centration and we would not expect this concentration to 
change so dramatically due to changes in protein binding. 
The acid dissociation constant (pKa) could make a difference 
in mixing and recovery, with cefazolin being a strong acid 
compared to clindamycin. To our knowledge, no influence of 
pKa on sequestration of drugs in CPB or ECMO circuits has 
been published before. During the experiments, clindamycin 
concentration seems to gradually increase to above 100% of 
the T1 concentration, but not to the MEC values. No previous 
results have been published on a potentially reversible bind-
ing of hydrophilic drugs to CPB compartments. However, 
considering our results this may be a potential explanation 
for the increasing clindamycin concentration or we may have 
an incomplete mixing of clindamycin that gradually evolves. 
We cannot completely exclude an error in medication admin-
istration or analysis. However, the CPB systems were run on 
several days and medication was always double-checked.
Our experiments show the effects of pediatric CPB sys-
tems on plasma concentration of cefazolin and clindamycin. 
Adequate concentration of cefazolin and clindamycin is im-
perative to prevent SSI. In children after cardiac surgery, SSI 
reportedly occurs in 1.9%-8% of patients.16 Correct plasma 
concentrations of antibiotics are a relatively easily modifiable 
factor to prevent SSI and are therefore important to investi-
gate in vitro and in vivo. As shown by Shah et al incorrect 
dosing of antibiotics gives a 1.7-fold increased risk of devel-
oping an SSI in pediatric patients.17 Suboptimal dosing due 
to the influence of the CPB system may affect the occurrence 
of SSI. To date, no uniform guidelines for the dosing of anti-
biotic prophylaxis in children are available. Also, potentially 
increased risks of SSI after cardiac surgery are not incorpo-
rated in current dosing advice.11 Several procedural risk fac-
tors, such as the use of a bladder catheter, longer duration of 
CPB or prolonged surgery time, may increase the risk of SSI 
in pediatric cardiac surgery patients.1 Our results show that 
the plasma cefazolin concentration only moderately decreases 
during CPB in the pediatric system. Cefazolin concentration 
remains stable over time in the neonatal and infant systems. 
The increased risk of SSI with longer CPB runtime may be 
associated with other surgery and patient-related factors, such 
as systemic inflammatory response syndrome (SIRS) and in-
creased volume of distribution with subsequent lower plasma 
concentration. The most important moment to obtain adequate 
plasma concentrations is at the time of wound closure. This 
should be investigated in vivo, with the added patient-related 
influence on plasma drug concentration. The loss of clinda-
mycin in the CPB systems, with the recovery of only 0.3%-
1.2% compared to the MEC, should be further investigated. If 
this indeed holds true, antibiotic prophylaxis with clindamycin 
is not effective for children undergoing cardiac surgery.
Our study has several limitations. First, we have not cor-
rected for the blood/plasma ratio of the measured drugs. 
For clindamycin, the blood/plasma ratio is not known. The 
blood/plasma ratio for cefazolin could potentially slightly 
change the measured plasma concentration. However, the 
measured concentrations are relatively high compared to 
clinically relevant values and therefore the blood/plasma 
ratio was not considered a large influence. Also, the blood/
plasma ratio remains constant over time and therefore does 
not influence the increase or decrease in the drug concen-
tration. Second, we did not correct for spontaneous degrada-
tion. Spontaneous degradation may introduce a potential bias 
in the measured plasma concentration, since this is a cause 
for drug loss. However, a study on the spontaneous degrada-
tion of cefazolin by Donnelly showed that cefazolin remains 
stable over 30 days.18 To our knowledge, no data have been 
published on clindamycin stability. From personal communi-
cation with our laboratory we know clindamycin to be stable 
for two years when kept at −20°C between processing and 
analysis, as is in line with good laboratory practice. Finally, 
during cardiac surgery, antibiotic administration is often re-
peated at the start of the CPB system. In contrast, we spiked 
the CPB systems at the beginning of the experiments and did 
not administer a redose during the experiment. This timing 
of administration only resembles short cardiac surgical pro-
cedures, without redosing at the onset of CPB. However, this 
method is often used in in vitro studies and most accurately 
reflects the influence of CPB runtime on drugs.
  Blood/plasma ratio LogP
Protein 
binding (%) Vd (L/kg) pKa
Cefazolin 1.21 −0.4 74-86 12 L 3.03 
(strongest 
acidic)
Clindamycin Unavailable 1.59 92-94 70 L 6.74 
(strongest 
basic)
Abbreviations: Vd, volume of distribution; pKa, acid dissociation constant at logarithmic scale; L, liter; Kg, 
kilogram; LogP, logarithm of partition coefficient.
T A B L E  5  Drug characteristics
ZEILMAKER-ROEST ET AL.8 |   
5  |  CONCLUSION
Our study shows a high recovery of cefazolin in the neo-
natal and infant CPB system, and the moderate recovery of 
cefazolin in the pediatric CPB system. We found a large dis-
crepancy between the MEC and measured concentrations of 
clindamycin in all tested CPB systems. Our results do not 
explain this discrepancy and this should be further investi-
gated to ensure adequate antibiotic prophylaxis in children 
undergoing cardiac surgery.
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